Tumor Necrosis Factor {alpha} and Colitis-Associated Colon Cancer

doi:10.1056/NEJMcibr0803116

A correction has been published: N Engl J Med 2008;359(26):2853.

Volume 358:2733-2734		June 19, 2008		Number 25

Tumor Necrosis Factor ${alpha}$ and Colitis-Associated Colon Cancer

Joanne A.P. Wilson, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

PDF

PDA Full Text

Purchase this article

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

Related Article

Colon cancer is one of the most serious complications of chronicinflammatory bowel disease. The cumulative risk ranges from2% among patients who have had colitis for 10 years to 18% amongpatients who have had colitis for 30 years.¹ A clinical trialof infliximab, a humanized monoclonal antibody against tumornecrosis factor ${alpha}$ (TNF- ${alpha}$ ), showed efficacy in the treatment ofpatients with moderate-to-severe ulcerative colitis.² A recentstudy by Popivanova and colleagues³ sheds light on some of themolecular mechanisms that may underlie this therapeutic effectand suggests a role for anti–TNF- ${alpha}$ antibodies in the preventionof colitis-associated colon . . . [Full Text of this Article]

Source Information

From the Department of Gastroenterology, Duke University Medical Center, Durham, NC.